drugset
drugset / Trial / NCT06462547

ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency

NCT06462547 ↗

Phase 2 Recruiting 200 enrolled Inozyme Pharma
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study (Study INZ701-304 \[ADAPT\]) is to assess the long-term safety of INZ-701 in patients with ENPP1 Deficiency or ABCC6 Deficiency who have received INZ-701 in an existing clinical study and choose to continue dosing for the potential treatment of their condition.

Timeline

Start
2024-06-19
Primary completion
2030-11
Completion
2030-12

Drugs

EvaluationDrugModalityDoseRoute
Subject INZ-701 Protein / enzyme biologic 1.8 mg/kg Subcutaneous
Subject INZ-701 Protein / enzyme biologic 2.4 mg/kg Subcutaneous
Subject INZ-701 Protein / enzyme biologic 150 mg Subcutaneous

Indications

calcinosis hypophosphatemic rickets, autosomal recessive, 2 pseudoxanthoma elasticum (inherited or acquired)